Elanco Animal Health Incorporated (NYSE:ELAN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $29.42.

A number of research firms have commented on ELAN. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They issued a “buy” rating and a $32.00 price target for the company. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, UBS Group increased their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $22.97 on Thursday. Elanco Animal Health has a 1-year low of $19.40 and a 1-year high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $11.48 billion, a PE ratio of -56.03, a price-to-earnings-growth ratio of 2.00 and a beta of 1.70. The firm’s 50 day simple moving average is $23.20 and its 200 day simple moving average is $23.83.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period last year, the firm earned $0.26 EPS. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts expect that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence Kurzius acquired 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Shiv O’Neill bought 3,998 shares of the stock in a transaction on Tuesday, August 18th. The shares were bought at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider directly owned 87,832 shares in the company, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steinberganna Wealth Management lifted its stake in Elanco Animal Health by 0.8% in the third quarter. Steinberganna Wealth Management now owns 62,123 shares of the company’s stock worth $1,391,000 after purchasing an additional 518 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of Elanco Animal Health in the 3rd quarter worth $41,000. Skylands Capital LLC boosted its stake in Elanco Animal Health by 1.1% in the third quarter. Skylands Capital LLC now owns 211,525 shares of the company’s stock valued at $4,736,000 after acquiring an additional 2,300 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Elanco Animal Health by 9.6% in the third quarter. Crossmark Global Holdings Inc. now owns 43,133 shares of the company’s stock valued at $966,000 after buying an additional 3,761 shares during the last quarter. Finally, Quadrant Capital Group LLC acquired a new stake in Elanco Animal Health in the 3rd quarter worth approximately $215,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.